PolyNovo (PNV) Short Interest Hits Record 13.26% — Full Analysis March 2026
PolyNovo (ASX:PNV) short interest has hit an all-time high of 13.26%, making it the #4 most shorted stock on the ASX. We dig into why it's so heavily shorted, the full 12-month short history, director buying, squeeze mechanics, and whether the setup is a buying opportunity.
PolyNovo Limited (ASX: PNV) has just reached a milestone that should make both bulls and bears pay attention: 13.26% of its shares are now sold short, the highest level ever recorded for the stock and enough to rank it the #4 most shorted company on the entire ASX as of 12 March 2026.
That's 91.6 million shares sold short. At the current price of $0.955, short sellers collectively owe $87.5 million worth of PNV stock back to lenders — on a company with a market cap of just $649 million.
This post uses ASIC short position data aggregated daily on ASXShort.app to provide the most comprehensive picture of PNV's short interest available anywhere. We cover the full 12-month history, daily short selling as a percentage of total volume, director trades, the securities lending pool, squeeze mechanics, and the fundamental case on both sides.
PNV Short Interest: The Current Numbers
| Metric | Value |
|---|---|
| Short Interest | 13.26% (all-time high) |
| Shares Short | 91,607,171 |
| Short Liability (AUD) | $87.5M |
| ASX Rank | #4 most shorted |
| Current Price | $0.955 |
| Market Cap | $649M |
| 52-Week High | $1.715 |
| 52-Week Low | $0.865 |
| Total Shares on Issue | 690.8M |
Data sourced from ASIC short position disclosures via ASXShort.app. Latest report date: 12 March 2026 (T+4 lag).
PNV Short Interest History: 12 Months of Data
This is where things get interesting. Short sellers haven't just been sitting at elevated levels — they've been methodically building a record position over the past 12 months.
| Date | Short % | Shares Short |
|---|---|---|
| 18 Mar 2025 | 7.34% | 50.7M |
| 25 Mar 2025 | 8.21% | 56.7M |
| 9 Apr 2025 | 10.15% | 70.1M |
| 15 May 2025 | 11.01% | 76.1M |
| 18 Jul 2025 | 11.07% | 76.5M |
| 8 Aug 2025 | 11.89% | 82.2M |
| 9 Sep 2025 | 12.56% | 86.8M |
| 18 Sep 2025 | 12.41% | 85.7M ← pre-squeeze peak |
| 19 Sep 2025 | 9.93% | 68.6M ← 17.1M shares covered in one day |
| 28 Oct 2025 | 10.70% | 73.9M |
| 10 Nov 2025 | 12.03% | 83.1M |
| 31 Dec 2025 | 11.57% | 80.0M |
| 20 Jan 2026 | 12.17% | 84.1M |
| 23 Feb 2026 | 12.89% | 89.0M |
| 12 Mar 2026 | 13.26% | 91.6M ← all-time high |
The pattern is clear. PNV started 2025 with a "normal" short interest of ~7%. By April it had breached 10%. Through August and September it pushed above 12%. The September 2025 squeeze momentarily knocked 17 million shares off the short book — but shorts rebuilt the entire position and then some within weeks. Today's 13.26% is higher than any level seen before or after that squeeze.
This is not a short position built on one thesis. It has been consistently added to through multiple news cycles, earnings reports, and even a violent squeeze event.
The September 2025 Short Squeeze: Why It Failed to Stick
On 19 September 2025, PNV short interest dropped from 12.41% (85.7M shares) to 9.93% (68.6M shares) in a single trading day. That's 17.1 million shares covered — roughly the equivalent of 10+ normal trading days of short covering happening simultaneously.
The reason wasn't a news-driven panic — it was mechanical. PNV was removed from the ASX 200 index, triggering forced selling by passive index funds and ETFs that track the benchmark. That sudden flood of index-rebalancing volume — shares changing hands that had to be sold regardless of price — gave short sellers a rare gift: massive liquidity to cover into without moving the price against themselves. In illiquid stocks like PNV, covering 17 million shares at once would normally cause a violent spike. The index removal provided the cover, literally.
This is a critical distinction. It wasn't shorts panicking and fleeing — it was savvy shorts using the passive flow as an exit ramp. The underlying conviction didn't waver.
Within weeks, the short position had climbed back above 10%, then 11%, then 12%. By November 2025 it was back near pre-squeeze levels, and by March 2026 it was at all-time highs. The bears didn't lose their nerve — they used the index removal as a chance to reload at lower prices after the rebalancing dust settled.
What this tells us: The short conviction here is extremely strong and the money behind it is sophisticated. These aren't weak hands; they actively managed their position around a structural event. That's a harder opponent for bulls to squeeze out.
Daily Short Selling as a % of Volume
Beyond the ASIC position data, ASX also publishes daily short sale volumes — how many shares are sold short on each trading day. This shows how active shorts are on any given day.
Recent daily short sale volumes for PNV:
| Date | Short Sales | Estimated % of Volume |
|---|---|---|
| 10 Mar 2026 | 2,102,495 | ~50–70% |
| 9 Mar 2026 | 1,932,303 | ~45–65% |
| 11 Mar 2026 | 1,515,063 | ~35–50% |
| 12 Mar 2026 | 923,426 | ~20–30% |
| 16 Mar 2026 | 967,603 | ~20–30% |
| 6 Feb 2026 | 2,189,300 | ~50–70% |
| 4 Feb 2026 | 2,306,718 | ~50–70% |
| 12 Feb 2026 | 2,213,469 | ~50–70% |
On the heaviest shorting days in early March 2026, short selling represented an estimated 50–70% of all PNV trading volume. This is extraordinary. For context, the ASX market-wide average for short sales as a percentage of daily volume is typically around 10–15%. PNV is running 3–5x the market average.
This level of daily short flow is actively suppressing the price. Every time organic buyers push the stock up, a wall of short sellers is meeting them with supply.
Why Is PNV So Heavily Shorted? The Bear Case
Understanding the short thesis is essential — these aren't random bets. Here's the cohesive bear case:
1. Valuation Disconnected from Earnings
At $0.955, PNV trades at approximately 49–94x trailing earnings depending on how you measure it, on a company that generated $13.2M NPAT in FY25. For a medical devices company, this is extremely demanding. The P/S ratio of ~5x implies the market expects years of continued hypergrowth to justify today's price.
Short sellers' argument: even with 29% revenue growth, the stock is priced to perfection at levels that leave no margin for error.
2. Single Product Concentration
NovoSorb BTM is essentially the entire business. If a competitor gets FDA approval for a cheaper or better product, if there's an adverse clinical event, or if the US burns market proves smaller than expected, there's no other revenue stream to fall back on.
Integra LifeSciences and Smith & Nephew have been in wound care for decades with massive sales forces, established hospital relationships, and diversified portfolios. PNV is a genuine innovator, but it's fighting for shelf space against entrenched incumbents.
3. US Growth Plateauing?
The core of the bear thesis: PNV has already captured the easy US wins (major burn centres), and incremental penetration into smaller facilities is slower and more expensive. The growth rate will inevitably decelerate, and when it does, the multiple collapses.
US sales grew 28.7% in FY25 ($88.4M). Bulls need that to continue at 25%+ for the next 3-5 years. Bears think it halves to 12-15% and the market reprices accordingly.
4. BARDA Revenue Is Not Commercial
Approximately $10M of annual revenue comes from a US government BARDA (Biomedical Advanced Research and Development Authority) contract for burn treatment stockpiling. This is government spending, not organic commercial demand. It can be modified, cut, or cancelled — and has been growing slowly. Strip it out and underlying commercial growth looks slightly less impressive.
5. Share Price Already Down 44% from Peak
PNV hit $1.715 in the past 12 months. It's now at $0.955 — down 44% from the high. Shorts who built positions at $1.40–1.70 are sitting on 30–45% profits. There's no urgency to cover.
The Bull Case: Why Shorts Could Be Very Wrong
Strong and Consistent Revenue Growth
| Period | Sales | Growth |
|---|---|---|
| FY24 | $92.0M | — |
| FY25 | $118.6M | +28.9% |
| H1 FY25 (to Dec 2024) | $54.1M | +28.1% YoY |
This is not manufactured growth. PNV has compounded revenue at 25-30%+ consistently. Operating leverage is now emerging — EBITDA went from $3.6M to $11.2-12.4M (+211%) in FY25, and NPAT went from $5.3M to $13.2M (+151%).
Cash Rich, No Existential Risk
Cash position: $33.5M with manageable debt. This is not a company at risk of a dilutive capital raise or going concern issues. The balance sheet supports continued investment without needing shareholder money.
The Diabetes Optionality
The islet cell transplant work with Beta Cell Technologies represents an option on a multi-billion dollar addressable market that is currently assigned zero value in most analyst models. Type 1 diabetes affects over 9 million people globally. If NovoSorb BTM can enable islet cell survival and function outside the liver — as the proof-of-concept suggests — this could be transformative.
It won't generate revenue for 5+ years. But options on markets this size don't stay at zero forever.
Analyst Consensus: Strong Buy
| Metric | Value |
|---|---|
| Consensus Rating | Strong Buy |
| Buy recommendations | 6 of 8 analysts |
| Hold recommendations | 2 of 8 |
| Sell recommendations | 0 |
| Average 12-month price target | $1.85–$2.01 |
| High target | $2.65 |
| Low target | $1.25 |
| Implied upside (from $0.955) | +94–110% |
Not a single analyst covering PNV has a sell rating. The average target implies roughly doubling from current levels. Zero sell ratings with 13.26% short interest — that's a striking divergence. Either analysts are wrong, or short sellers are wrong.
Director Buying: Insiders Are Loading Up
This is where the bull case gets particularly compelling. Director trades data from ASXShort.app shows two separate directors buying PNV shares in the past month, at the lowest prices in over a year:
| Date | Director | Action | Shares | Value (~AUD) |
|---|---|---|---|---|
| 12 Mar 2026 | Robert Douglas | BUY | 151,000 | ~$144k |
| 25 Feb 2026 | Leon Hoare | BUY | 30,000 | ~$29k |
Robert Douglas opened a completely new position — he previously held zero shares in the company and just put $144,000 of his own money in at ~$0.955. This is a director opening a fresh bet on the company at multi-year lows.
For context, David Williams (chairman) was also buying in September 2025 during the aftermath of the diabetes announcement squeeze, picking up 68,000+ shares at ~$1.39–1.40.
Directors have full visibility into commercial pipeline, US sales trajectory, pipeline progress, and operational data that outside investors can't access. When multiple directors are buying at these prices while short sellers are at record levels, someone has seriously misjudged the situation.
Securities Lending: Who's Borrowing the Shares?
To short a stock, you first need to borrow shares. ASXShort.app's securities lending data shows the depth of the borrow market for PNV:
Total shares borrowed: 188.5M | Total shares lent: 122.2M
Top borrowers (institutions holding borrowed PNV shares, typically to facilitate shorting):
| Institution | Shares Borrowed |
|---|---|
| Merchant Group Trust | 60,000,000 |
| State Street Global Advisors | 24,857,178 |
| Citibank N.A. Sydney Branch | 23,277,478 |
| UBS AG Australia Branch | 17,431,002 |
| J.P. Morgan Securities PLC | 14,644,555 |
The short position is held by 26 separate borrowing entities — this is not one concentrated short. It's institutionally distributed across global prime brokers and hedge funds. This makes a forced-cover scenario harder to engineer artificially, but a fundamental catalyst squeeze (strong earnings, major pipeline news) could still trigger simultaneous covering across all these parties.
Short Squeeze Mechanics: Days to Cover
The key metric for squeeze potential is days to cover — how long it would take to unwind the entire short position at normal trading volumes.
- Shares short: 91.6M
- Average daily volume: ~1.5–2M shares (normal days)
- Days to cover at normal volume: ~45–60 trading days
This is one of the highest days-to-cover figures on the ASX. For reference:
- At 5M shares/day (heavy activity): still 18+ trading days to unwind
- At 10M shares/day (extreme, like during the Sep 2025 squeeze): still 9 days
The September 2025 event saw ~17M shares covered in a single day — that was about $24M of forced buying hitting the market at once. If a major catalyst hit today with the short position 7% larger than then, the dynamics would be even more violent.
The squeeze is not impossible. It's just hard. And slow. And requires a genuine catalyst.
Peer Comparison
How does PNV's short interest compare to its peer group?
| Company | Market | Revenue Growth | Short Interest |
|---|---|---|---|
| PolyNovo (PNV) | ASX | +29% | 13.26% |
| Integra LifeSciences (IART) | NASDAQ | +3–5% | ~3% |
| Smith & Nephew (SNN) | LSE | +4–6% | ~1% |
| Avita Medical (AVH) | ASX | high growth | ~2–4% |
| Wound care sector average | — | 3–6% | 1–3% |
PNV is growing at 5–10x the rate of global wound care peers, yet carries 4–13x their short interest. The short sellers' implicit bet is that this growth trajectory ends, and that the premium valuation corrects accordingly.
Is PNV a Buy at Current Levels?
The setup has several features that historically precede significant moves:
Factors supporting a bull case:
- Record short interest (maximum pessimism, maximum fuel for covering)
- Zero analyst sell ratings with ~100% consensus upside to target
- Active director buying (new 151k position opened March 12 at current prices)
- Consistent 28-29% revenue growth with improving profitability
- $33.5M cash, no balance sheet risk
- Diabetes optionality = free call option on a massive market
- 44% drawdown from 52-week high despite no deterioration in fundamentals
Factors supporting the bear case:
- Shorts are smart money and they're at record levels — they didn't come here to lose
- PE of ~49x is demanding for a single-product medical device company
- Sep 2025 showed shorts can absorb a squeeze and rebuild
- Earnings in absolute dollars are still small relative to market cap
- US market penetration may be reaching natural limits
The honest assessment: At $0.955 with the stock near 52-week lows and directors buying, the risk/reward is skewed to the upside over a 12–18 month horizon. The downside is roughly 9% to the 52-week low of $0.865. The upside to the analyst consensus target is 94–110%. That's a 10:1 ratio.
The question is: can you hold through the ongoing short-selling pressure and potential further weakness before the catalyst arrives?
If you can — and if you believe the US growth story continues — the short data itself becomes part of the bull case. Ninety-one million shares need to be bought back eventually.
Track PNV Short Interest in Real Time
ASXShort.app is Australia's most comprehensive short selling tracker. We aggregate ASIC short position disclosures daily (T+4), show daily ASX short sale volumes, director trades, and securities lending data — all in one place, all free.
You can also set up alerts to be notified when PNV's short position changes significantly.
All short position data sourced from ASIC mandatory short position disclosures, aggregated and published on ASXShort.app. Director trade data sourced from ASX Appendix 3Y/3X filings. This post is for informational purposes only and is not financial advice. Short selling involves significant risk. Fundamental data sourced from company announcements and ASX filings. Analyst consensus data from third-party aggregators. Past performance is not indicative of future results.
Last updated: 18 March 2026.